LABELS · 3438144a-8319-4971-981b-38f13201b980

Premarin

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-04-02
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA See full prescribing information for complete boxed warning. Estrogen-Alone Therapy • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 ) • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) • Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) ( 5.1 ) • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen Plus Progestin Therapy • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) ( 5.1 ) • The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer ( 5.2 ) • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ]. Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3) , and Clinical Studies (14.5, 14.6) ] . The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ]. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3) , and Clinical Studies (14.5 , 14.6) ]. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5) ] . The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2) , and Clinical Studies (14.5) ]. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Indications and usage: exact source text

1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered

Full extracted label fields

application numbers

NDA004782

boxed warning exact

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA See full prescribing information for complete boxed warning. Estrogen-Alone Therapy • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 ) • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) • Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) ( 5.1 ) • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen Plus Progestin Therapy • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) ( 5.1 ) • The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer ( 5.2 ) • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ]. Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3) , and Clinical Studies (14.5, 14.6) ] . The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ]. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3) , and Clinical Studies (14.5 , 14.6) ]. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5) ] . The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3) , Use in Specific Populations (8.5) , and Clinical Studies (14.6) ] . Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2) , and Clinical Studies (14.5) ]. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

brand names

Premarin

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b86b85-8923-42ae-aa31-a66a6e090327

generic names

ESTROGENS, CONJUGATED

3438144a-8319-4971-981b-38f13201b980

indications and usage exact

1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered

indications and usage tables exact

is original packager

manufacturer names

A-S Medication Solutions

matched search terms

cancer
carcinoma

package ndcs

50090-0167-5
50090-0167-0

product ndcs

50090-0167

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions, Malignant Neoplasms ( 5.2 ) 2/2024

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

150840
310197

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA004782

brand names

Premarin

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 273
end exclusive: true
exact text: 1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 0

current approval status

not_reconciled

duplicate text group

dup-f4bac36c9bb288770e8e

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-dacc40450e8297dd4e17

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

end: 68
end exclusive: true
exact text: is a mixture of estrogens indicated
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 73
end exclusive: true
exact text: 1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for:
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 351
end exclusive: true
exact text: 1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 0

current approval status

not_reconciled

duplicate text group

dup-222a08d8f63898beba46

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-0611617fbd116e5c721d

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 151
end exclusive: true
exact text: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 74

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 437
end exclusive: true
exact text: 1 INDICATIONS AND USAGE PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metas
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 0

current approval status

not_reconciled

duplicate text group

dup-9a0e8e20960003cb368b

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-e9a0cd4fb2c228dba55c

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 237
end exclusive: true
exact text: • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 152

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 535
end exclusive: true
exact text: mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Pa
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 38

current approval status

not_reconciled

duplicate text group

dup-00eaed2458bab8815ef6

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-a32e85b68f2a96b75835

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 335
end exclusive: true
exact text: • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 238

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 658
end exclusive: true
exact text: nopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Sy
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 136

current approval status

not_reconciled

duplicate text group

dup-ef4c875c74d8acd5b80e

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-fdefe83f54976da1394f

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

context exact
lliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 )
kind
biomarker
polarity
not_inferred
span
end
454
end exclusive
true
exact text
Metastatic Disease ( 1
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
432
context exact
lliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 )
kind
stage_or_setting
polarity
not_inferred
span
end
454
end exclusive
true
exact text
Metastatic Disease ( 1
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
432

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 458
end exclusive: true
exact text: • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 336

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 757
end exclusive: true
exact text: trogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 259

current approval status

not_reconciled

duplicate text group

dup-f106798ac76e27fc8766

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-6cecf93315625a7b334b

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

context exact
• Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
517
end exclusive
true
exact text
Advanced Androgen-Dependent Carcinoma of th
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
474

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 557
end exclusive: true
exact text: • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 459

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 809
end exclusive: true
exact text: Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 358

current approval status

not_reconciled

duplicate text group

dup-50677817e0fcecc8eff4

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-6c52e3076df421b00709

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 609
end exclusive: true
exact text: • Prevention of Postmenopausal Osteoporosis ( 1.6 )
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 558

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 881
end exclusive: true
exact text: ed Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and va
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 410

current approval status

not_reconciled

duplicate text group

dup-eb90752e7cf972436c09

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-5f832f12253368235c13

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 681
end exclusive: true
exact text: 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 610

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · positive indication candidate

application numbers

NDA004782

brand names

Premarin

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1159
end exclusive: true
exact text: Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastati
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 482

current approval status

not_reconciled

duplicate text group

dup-4c40992bf6c3c1932b5e

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-07fe2941ce0aca28af0e

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

end: 68
end exclusive: true
exact text: is a mixture of estrogens indicated
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 959
end exclusive: true
exact text: 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered.
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 682

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1251
end exclusive: true
exact text: to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Pallia
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 760

current approval status

not_reconciled

duplicate text group

dup-74e8b50f973daae19553

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-afd8f4381be8c525ebc1

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1051
end exclusive: true
exact text: 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 960

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1368
end exclusive: true
exact text: ere symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 852

current approval status

not_reconciled

duplicate text group

dup-e6e6dc5a39dfb40ac706

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-301e82c95739bb022b78

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

context exact
lliation Only) in Appropriately Selected Women and Men with Metastatic Disease
kind
biomarker
polarity
not_inferred
span
end
1168
end exclusive
true
exact text
Metastatic Disease
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
1150
context exact
lliation Only) in Appropriately Selected Women and Men with Metastatic Disease
kind
stage_or_setting
polarity
not_inferred
span
end
1168
end exclusive
true
exact text
Metastatic Disease
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
1150

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1168
end exclusive: true
exact text: 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 1052

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA004782

brand names

Premarin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1461
end exclusive: true
exact text: ment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant r
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 969

current approval status

not_reconciled

duplicate text group

dup-cb439dcb3864df72fb97

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-6b943c361c8e19717bf4

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

context exact
1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only)
kind
stage_or_setting
polarity
not_inferred
span
end
1229
end exclusive
true
exact text
Advanced Androgen-Dependent Carcinoma of th
label id
3438144a-8319-4971-981b-38f13201b980
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start
1186

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1261
end exclusive: true
exact text: 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only)
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 1169

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · risk or warning

application numbers

NDA004782

brand names

Premarin

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1539
end exclusive: true
exact text: ent of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 1062

current approval status

not_reconciled

duplicate text group

dup-c35aec9ccdad90d71de3

extraction review status

automated_candidate_pending_source_review

generic names

ESTROGENS, CONJUGATED

ind-span-0ed0cf5ddbe49570815f

label id

3438144a-8319-4971-981b-38f13201b980

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1539
end exclusive: true
exact text: 1.6 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered
label id: 3438144a-8319-4971-981b-38f13201b980
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 39878fd76adbd9a76993a00d4bd9a94bee4bd0782eb02d8d936cbee215561679
start: 1262

source url

https://api.fda.gov/drug/label.json?search=id%3A%223438144a-8319-4971-981b-38f13201b980%22

spl effective date

2025-04-02

spl set id

a3b86b85-8923-42ae-aa31-a66a6e090327

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice